CSIMarket
 
Allarity Therapeutics Inc   (NASDAQ: ALLR)
 
Price: $1.3150 $0.07 5.200%
Day's High: $1.340000033378601 Week Perf: -7.39 %
Day's Low: $ 1.26 30 Day Perf: -6.07 %
Volume (M): 128,313 52 Wk High: $ 1.84
Volume (M$): $ 0 52 Wk Avg: $1.28
Open: $1.32 52 Wk Low: $0.77



 Market Capitalization (Millions $) 21
 Shares Outstanding (Millions) 16
 Employees 8
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) 11
 Capital Exp. (TTM) (Millions $) 0

Business Description


Allarity Therapeutics Inc. is a biotechnology company headquartered in Denmark. The company focuses on developing personalized medicine and innovative drug discovery solutions for the treatment of cancer. Their proprietary drug response predictor (DRP) technology helps identify which patients are likely to respond positively to certain drug treatments, based on molecular profiling and analysis.

Allarity Therapeutics aims to optimize the use of existing drugs and accelerate the development of new therapies by identifying and targeting specific patient populations that will benefit the most. Their DRP technology evaluates the unique genetic profile of each patient to tailor treatments and improve clinical outcomes. This personalized approach has the potential to significantly improve patient care and reduce healthcare costs by avoiding ineffective treatments.

The company's pipeline includes several drug candidates in various stages of development for targeted cancer treatments. Allarity Therapeutics collaborates with research institutions, academic partners, and pharmaceutical companies to advance their drug development programs. Their goal is to bring effective therapies to the market and improve the lives of cancer patients worldwide.


   Company Address: 123 E Tarpon Ave Tarpon Springs 34689 FL
   Company Phone Number: 426-4664   Stock Exchange / Ticker: NASDAQ ALLR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ   -3.42%    
MRK   -5.04%    
PFE   -4.46%    
TEVA   -1.47%    
VRTX   -8.07%    
VTRS   -2.95%    
• View Complete Report
   



Announcement

Pioneering Advances in Ovarian Cancer Treatment Allarity Therapeutics Showcases Progress with Stenoparib and Innovati...

Published Mon, Sep 22 2025 12:22 PM UTC

Allarity Therapeutics, Inc. is making significant strides in the realm of oncology, particularly with its promising drug candidate, stenoparib, in the treatment of platinum-resistant ovarian cancer. Recent clinical data presented by the company highlights an important milestone: the median overall survival (OS) for patients receiving stenoparib/2X-121 has surpassed 25 months...

Announcement

Allarity Therapeutics Advances Share Repurchase Program Amid Promising Developments in Stenoparib Clinical Trials

Published Fri, Jun 20 2025 4:45 PM UTC

for CSIMarket.com On March 3, 2025, Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage pharmaceutical company focused on developing personalized cancer therapies, announced an authorization from its Board of Directors for a share repurchase program amounting to $5 million. This program is to be executed through February 28, 2026, as part of a broader strategy t...

Announcement

Allarity Therapeutics Announces Changes to Board of Directors Amid Strategic Developments in Cancer Treatment

Published Thu, Jun 12 2025 9:37 AM UTC

Allarity Therapeutics, Inc. (NASDAQ: ALLR), a pharmaceutical company focused on advancing personalized cancer therapies, has announced a significant change in its Board of Directors. Effective June 30, 2025, Jesper Hiland will be appointed to the board, taking the position previously held by Joseph Vazzano, who will step down after serving for two years.Allarity focuses on d...

Announcement

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Tria...

Published Sun, May 11 2025 8:16 AM UTC

Allarity Therapeutics: Pioneering the Future of Ovarian Cancer Treatment with StenoparibIn a recent update, Allarity Therapeutics (NASDAQ: ALLR) shed light on its first quarter of 2025, revealing promising advancements in its flagship compound, Stenoparib. The therapeutic agent continues to demonstrate significant clinical benefits, particularly for patients grappling with ...

Announcement

Allarity Therapeutics Poised for Milestones Amid Legal Challenges and Market Compliance

Published Mon, Feb 24 2025 1:32 PM UTC

Boston (February 24, 2025) In an exciting development for oncology research, Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company, has announced the initiation of enrollment for a new Phase 2 clinical trial protocol focused on its innovative treatment, stenoparib. Targeted toward patients suffering from advanced ovarian cancer, this ...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 60.65
Price to Sales (Expected) -
Price to Book 5.92
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.59
Working Capital Ratio 1.11
Leverage Ratio (MRQ) 8.08
Total Debt to Equity 5.9
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.8 $
Revenues (TTM) 0.02 $
Cash Flow (TTM) 0.67 $
Cash 1.07 $
Book Value 0.22 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,541,750
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.